intensity) between patients in different stages of OA is scarce. Also, comparisons with the general population are understudied. Objectives: To compare the amount (i.e. duration and intensity) of PA in patients in different stages of OA (i.e. patients in primary and secondary care, and post Total Joint Arthroplasty (TJA)) and the general population. Methods: This study is based on secondary analyses of baseline data from four studies: 1 an effectiveness study of an educational program for OA

more »

... ients in primary care, 2 a study on effectiveness of a multidisciplinary self-management program for generalised OA in secondary care, 3 a study among patients whom underwent TJA for end-stage OA in preceding 7-22 months, and 4 a nationwide study among the general population in the Netherlands (n=14,000) on general health. 1 In the current study only patients aged !40 years were included. The SQUASH questionnaire was used to assess PA in all 4 studies and to calculate adherence to PA recommendations, duration (hrs/wk) and intensity (MET.hrs/wk). To compare the amount (hrs/wk) and intensity (MET.hrs/wk) between different stages of OA and the general population, we applied multiple linear regression analysis, adjusted for age, gender and Body Mass Index (BMI). Results: Demographic characteristics and adherence to PA recommendations are illustrated in table 1. Mean duration and intensity of PA in the general population were 41.3 hrs/week and 145.7 MET.hrs/week, respectively. Patients after TJA showed higher PA levels (both in terms of duration and intensity) than patients in secondary care and the general population (table 2) . Table 1 . Demographic characteristics of three OA stages and the general population in the Netherlands Primary care n=117 Secondary care n=144 Abstract FRI0552 -Figure 1. SM04690 inhibited inflammatory cytokine production in synovial fibroblasts in vitro Abstract FRI0552 -Figure 2. SM04690 inhibited inflammatory cytokine production and decreased inflammation and pain in the MIA model of OA Conclusions: In a rat MIA OA model, SM04690 injection reduced inflammation, protease production, and pain, with improved cartilage and joint health, compared to vehicle. Previously demonstrated regenerative effects in nonclinical studies 1 , along with anti-inflammatory properties, show SM04690 may improve symptoms and potentially provide disease modification in OA. Clinical studies are ongoing. REFERENCE: [1] Deshmukh V, et al. Osteoarthritis Cartilage 2018;26:18-27.